Information Provided By: 
Fly News Breaks for October 13, 2016
FMS, DVA, ARA
Oct 13, 2016 | 07:51 EDT
SunTrust analyst David MacDonald lowered his price targets on dialysis stocks, citing CMS' recent request for information and resulting payor risk and lower assumed multiples. The analyst cut his price target on American Renal Associates (ARA) to $24 from $34, on DaVita (DVA) to $66 from $80 and on Fresenius Medical (FMS) to $48 from $54. He maintains Buy ratings on American Renal and Fresenius but said he does not expect the stocks to rise significantly until the CMS matter is resolved. MacDonald keeps a Hold rating on DaVita.
News For ARA;DVA;FMS From the Last 2 Days
There are no results for your query ARA;DVA;FMS
